Norden Group LLC Acquires 341 Shares of Repligen Co. (NASDAQ:RGEN)

Norden Group LLC lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 10.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,698 shares of the biotechnology company’s stock after purchasing an additional 341 shares during the period. Norden Group LLC’s holdings in Repligen were worth $532,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the company. Ballentine Partners LLC grew its holdings in Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 72 shares during the last quarter. CIBC Asset Management Inc grew its holdings in Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 81 shares during the last quarter. MML Investors Services LLC grew its holdings in Repligen by 2.7% in the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after acquiring an additional 89 shares during the last quarter. GAMMA Investing LLC grew its holdings in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its holdings in Repligen by 0.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RGEN shares. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $181.00.

Repligen Price Performance

Shares of RGEN stock opened at $155.38 on Tuesday. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of -304.67, a PEG ratio of 4.54 and a beta of 0.99. The business’s fifty day moving average is $156.37 and its 200 day moving average is $148.43. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $203.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.